MedTech Dive January 18, 2022
After proving fairly resilient throughout the last two years, even as other medtechs were hit by the pandemic, Dexcom may have felt its first pandemic-pressured quarter. Although, the continuous glucose monitor maker still met expectations.
In the fourth quarter, Dexcom expects revenue of approximately $698 million, about 23% growth over the prior year’s quarter, according to the company’s pre-announcement last week. For the full year, revenue is expected to jump year over year by more than 27% to nearly $2.5 billion.
While the fourth-quarter results were in line with Dexcom’s guidance and Wall Street’s expectations, the results did not beat the marks by as much as the company has in the past.
CEO Kevin Sayer told MedTech Dive that the...
Today's Sponsors
Today's Sponsor